During the past decade, Nihon University Itabashi Hospital conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 15 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 12 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nihon University Itabashi Hospital" #1 sponsor was "Boehringer Ingelheim" with 8 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "Incyte Corporation" with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored and "Japan Rhabdomyosarcoma Study Group" with 2 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nihon University Itabashi Hospital" #1 collaborator was "Boehringer Ingelheim" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "Chugai Pharmaceutical Co." with 1 trials as a collaborator and "Japan Clinical Oncology Group" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Nihon University Itabashi Hospital" are "Systemic Lupus Erythematosus" (3 trials), "Atrial Fibrillation" (2 trials), "Coronary Artery Disease" (2 trials), "Heart Failure" (2 trials) and "Sarcoma" (2 trials). Many other conditions were trialed in "Nihon University Itabashi Hospital" in a lesser frequency.

Most popular intervention types in "Nihon University Itabashi Hospital" are "Drug" (29 trials), "Biological" (5 trials), "Device" (4 trials), "Other" (4 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Faricimab" (3 trials), "Sham Procedure" (3 trials), "Aflibercept" (2 trials) and "Nipocalimab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Nihon University Itabashi Hospital" are 37 trials for "All" genders.

Currently, there are NaN active trials in "Nihon University Itabashi Hospital". undefined are not yet recruiting, 9 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Nihon University Itabashi Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Nihon University Itabashi Hospital, 2 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".